According to The Australian Financial Review, an Australian start-up developing a vaccine against one of the world’s most prolific bacterial pathogens – one which is responsible for causing a wide range of illnesses from middle ear infections to life-threatening pneumonia – has scored a $300 million valuation as part of its latest funding round.
GPN Vaccines has raised $US12 million ($18 million) in a round led by New York-based Forepont Capital, San Francisco’s Kern Capital and the founding partner of local fund Shearwater Capital, Mike Gregg. The company has already conducted a phase-one trial of its Streptococcus pneumoniae vaccine in 50 to 69 year olds, which found it was safe and well tolerated at a variety of dosages and able to induce an antibody response relative to the dosage. https://www.afr.com/companies/healthcare-and-fitness/aussie-vaccine-start-up-scores-300m-valuation-20240530-p5ji1w
0 Comments
Leave a Reply. |
Subscribe to our English Newsletter
AuthorHarry Kinase Archives
October 2024
Categories
All
|
Getting Around
Home | About us | Our Services | Column | Blog | Contact | Website term of use
Subscribe to our English Newsletter
|
日本語ニュースレター配信登録
© Japan Australia Business Creators Pty Ltd | All Rights Reserved. Website designed and developed by Japan Australia Business Creators Pty Ltd.